GELSOMINO, FRANCESCO
 Distribuzione geografica
Continente #
EU - Europa 887
NA - Nord America 434
AS - Asia 118
AF - Africa 11
SA - Sud America 7
OC - Oceania 1
Totale 1.458
Nazione #
FR - Francia 669
US - Stati Uniti d'America 430
IT - Italia 63
DE - Germania 34
CN - Cina 32
GB - Regno Unito 26
IE - Irlanda 26
IN - India 20
BG - Bulgaria 15
SE - Svezia 11
TW - Taiwan 10
TR - Turchia 9
ES - Italia 8
HK - Hong Kong 8
EG - Egitto 7
JP - Giappone 7
KR - Corea 7
NL - Olanda 6
CZ - Repubblica Ceca 5
FI - Finlandia 5
IL - Israele 5
SG - Singapore 5
CA - Canada 4
AE - Emirati Arabi Uniti 3
AR - Argentina 3
BR - Brasile 3
HU - Ungheria 3
PL - Polonia 3
SI - Slovenia 3
VN - Vietnam 3
DZ - Algeria 2
GR - Grecia 2
MK - Macedonia 2
MY - Malesia 2
PH - Filippine 2
SA - Arabia Saudita 2
TH - Thailandia 2
ZA - Sudafrica 2
AU - Australia 1
CL - Cile 1
DK - Danimarca 1
IQ - Iraq 1
LV - Lettonia 1
PT - Portogallo 1
RU - Federazione Russa 1
SK - Slovacchia (Repubblica Slovacca) 1
UA - Ucraina 1
Totale 1.458
Città #
Paris 137
Ashburn 63
Santa Cruz 44
Dublin 26
Fairfield 18
Seattle 18
Chicago 16
Southend 16
Sofia 14
Buffalo 13
Boardman 10
Houston 10
New York 10
San Diego 10
Cambridge 9
Los Angeles 9
Bremen 8
Stockholm 8
Taipei 8
Ankara 6
Florence 6
Woodbridge 6
Beijing 5
Bologna 5
Washington 5
Council Bluffs 4
Dallas 4
Folignano 4
Giv‘atayim 4
Helsinki 4
Las Vegas 4
Mountain View 4
Naples 4
Phoenix 4
Seongbuk-gu 4
Shanghai 4
Valencia 4
Bengaluru 3
Buenos Aires 3
Cairo 3
Clearwater 3
Debrecen 3
Dong Ket 3
Guangzhou 3
Gurgaon 3
Milan 3
Newton 3
Provo 3
Southwark 3
Toronto 3
Wilmington 3
Amsterdam 2
Ann Arbor 2
Bhubaneswar 2
Busanjin-gu 2
Bydgoszcz 2
Campina Grande 2
Cankaya 2
Central District 2
Cesena 2
Chang-hua 2
Chennai 2
Chongqing 2
Columbus 2
Crugers 2
Dongguan 2
Dubai 2
Frankfurt am Main 2
Groningen 2
Herndon 2
Kolkata 2
Litija 2
Marseille 2
Milpitas 2
Montefalco 2
Portland 2
Quezon City 2
Rome 2
San Jose 2
Seri Kembangan 2
Shenzhen 2
Skopje 2
Tianjin 2
Tokyo 2
Torino 2
Abano Terme 1
Athens 1
Atlanta 1
Auburn 1
Badajoz 1
Bangalore 1
Bloomsbury 1
Bordj Bou Arreridj 1
Boulder 1
Bratislava 1
Bunkyo-ku 1
Burgas 1
Chengdu 1
Chieti 1
Clifton Park 1
Totale 653
Nome #
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System, file e1dcb339-a40a-7715-e053-1705fe0a6cc9 640
Pembrolizumab in the treatment of metastatic non-small cell lung cancer: A review of current evidence, file e1dcb335-794d-7715-e053-1705fe0a6cc9 131
Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer, file e1dcb338-7cc2-7715-e053-1705fe0a6cc9 129
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players?, file e1dcb336-1a59-7715-e053-1705fe0a6cc9 74
IFN-γ and CD38 in Hyperprogressive Cancer Development, file e1dcb336-8df3-7715-e053-1705fe0a6cc9 73
New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event, file e1dcb335-f1fe-7715-e053-1705fe0a6cc9 69
Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study, file e1dcb337-8831-7715-e053-1705fe0a6cc9 64
Next-generation technologies in predictive molecular pathology of lung cancers, file a3d6f10f-1b68-4da5-99f1-c21e5c664d02 60
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial), file e1dcb336-5872-7715-e053-1705fe0a6cc9 53
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC, file e1dcb333-7222-7715-e053-1705fe0a6cc9 51
Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer, file e1dcb336-5975-7715-e053-1705fe0a6cc9 49
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance, file e1dcb336-bed1-7715-e053-1705fe0a6cc9 34
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System, file e1dcb339-40e3-7715-e053-1705fe0a6cc9 27
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance, file e1dcb339-da19-7715-e053-1705fe0a6cc9 10
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL), file fe9c4c5b-003d-421d-a25e-b2f2578e9070 8
Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial, file 41af414d-8d33-4bf7-a39b-fe9feaa9c0a6 4
Peripheral nervous system adverse events associated with immune checkpoint inhibitors, file 77ec4bf0-41ef-4b01-a932-4634ebeca082 3
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL), file 4ef3cbb4-e7aa-402f-9e76-651d3c247b45 1
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC, file e1dcb331-f63f-7715-e053-1705fe0a6cc9 1
Totale 1.481
Categoria #
all - tutte 3.824
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.824


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204 0 0 0 0 0 0 0 0 0 1 2 1
2020/202186 6 0 4 3 2 4 5 6 11 13 19 13
2021/2022260 11 11 10 13 29 18 10 10 24 25 64 35
2022/2023280 15 13 48 43 10 15 19 11 35 16 40 15
2023/2024850 13 12 9 31 18 518 33 124 80 12 0 0
Totale 1.481